Results from the more recent phase 2 BYLieve study indicate that alpelisib in combination with endocrine therapy (fulvestrant or letrozole) is also effective in patients with HR+, HER2–, PIK3CA-mutated breast cancer in the post-CDK4/6 inhibitor setting [16,18]. The gene discussed is HR; the disease is breast cancer.